JP2018513104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513104A5 JP2018513104A5 JP2017534274A JP2017534274A JP2018513104A5 JP 2018513104 A5 JP2018513104 A5 JP 2018513104A5 JP 2017534274 A JP2017534274 A JP 2017534274A JP 2017534274 A JP2017534274 A JP 2017534274A JP 2018513104 A5 JP2018513104 A5 JP 2018513104A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nanoparticles
- cancer
- malignant tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000002105 nanoparticle Substances 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 108091030071 RNAI Proteins 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 101150018337 Serpinh1 gene Proteins 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014266198 | 2014-12-26 | ||
| JP2014266198 | 2014-12-26 | ||
| US201562184195P | 2015-06-24 | 2015-06-24 | |
| US62/184,195 | 2015-06-24 | ||
| US201562266670P | 2015-12-13 | 2015-12-13 | |
| US62/266,670 | 2015-12-13 | ||
| PCT/US2015/067558 WO2016106403A2 (en) | 2014-12-26 | 2015-12-28 | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513104A JP2018513104A (ja) | 2018-05-24 |
| JP2018513104A5 true JP2018513104A5 (enExample) | 2019-02-14 |
Family
ID=56151549
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
| JP2017534274A Pending JP2018513104A (ja) | 2014-12-26 | 2015-12-28 | Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法 |
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Active JP7655971B2 (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2025046972A Pending JP2025102833A (ja) | 2014-12-26 | 2025-03-21 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Active JP7655971B2 (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2025046972A Pending JP2025102833A (ja) | 2014-12-26 | 2025-03-21 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US10264976B2 (enExample) |
| EP (9) | EP3236969A4 (enExample) |
| JP (10) | JP6793649B2 (enExample) |
| KR (4) | KR20170093988A (enExample) |
| CN (7) | CN107108686B (enExample) |
| AU (4) | AU2015369598A1 (enExample) |
| BR (2) | BR112017013597B1 (enExample) |
| CA (4) | CA2972265A1 (enExample) |
| RU (4) | RU2756253C2 (enExample) |
| WO (7) | WO2016106402A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| ES2789049T3 (es) * | 2014-12-26 | 2020-10-23 | Nitto Denko Corp | Agentes de interferencia de ARN para modulación génica de GST-pi |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| CN107708739A (zh) | 2015-06-24 | 2018-02-16 | 日东电工株式会社 | 可电离化合物、组合物及它们的用途 |
| KR102740699B1 (ko) | 2015-12-13 | 2024-12-09 | 닛토덴코 가부시키가이샤 | 높은 활성 및 감소한 오프 타겟을 위한 sirna 구조 |
| JP7177439B2 (ja) | 2016-05-10 | 2022-11-24 | 国立大学法人 東京医科歯科大学 | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 |
| JP2019508379A (ja) * | 2017-02-16 | 2019-03-28 | 日東電工株式会社 | 悪性腫瘍に対する治療方法及び治療用組成物 |
| CN111386105B (zh) * | 2017-11-06 | 2023-09-15 | 日东电工株式会社 | 用于递送生物活性分子的膜融合化合物 |
| CA3082006A1 (en) * | 2017-11-09 | 2019-05-16 | National University Corporation Tokyo Medical And Dental University | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnosticmethod |
| CN109777798A (zh) * | 2017-11-13 | 2019-05-21 | 深圳华大生命科学研究院 | 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用 |
| JP6952594B2 (ja) * | 2017-12-15 | 2021-10-20 | 洋司郎 新津 | 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 |
| CN108486011B (zh) * | 2018-03-27 | 2020-05-05 | 山东大学 | 一种三联苯化合物、制备方法及其应用 |
| JP7432929B2 (ja) * | 2018-05-31 | 2024-02-19 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途 |
| WO2020009189A1 (ja) * | 2018-07-05 | 2020-01-09 | 洋司郎 新津 | Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤 |
| EP3848050A4 (en) * | 2018-08-22 | 2022-06-08 | Nitto Denko Corporation | DRUG USING AN HSP47 INHIBITOR TO INCREASE SENSITIVITY TO A CHEMOTHERAPY DRUG |
| CN112739381A (zh) * | 2018-08-22 | 2021-04-30 | 日东电工株式会社 | 使用了hsp47的抑制物质的癌转移抑制 |
| US11708575B2 (en) * | 2018-11-16 | 2023-07-25 | Nitto Denko Corporation | RNA interference delivery formulation and methods for malignant tumors |
| JPWO2020116537A1 (ja) * | 2018-12-05 | 2021-10-21 | 日東電工株式会社 | がん処置用ＲＮＡｉ分子 |
| EP3909588A4 (en) | 2019-01-10 | 2023-01-04 | Osaka University | IMMUNO-STIMULATING COMPOSITION |
| US20220170022A1 (en) * | 2019-03-28 | 2022-06-02 | Nitto Denko Corporation | Rnai molecule |
| JP2019116507A (ja) * | 2019-04-25 | 2019-07-18 | 有限会社オービット | Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法 |
| EP3965781A2 (en) * | 2019-07-02 | 2022-03-16 | Argonaute Rna Limited | Apolipoprotein b antagonist |
| JP7692829B2 (ja) * | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| US20230061751A1 (en) * | 2020-01-17 | 2023-03-02 | University Of Massachusetts | Universal dynamic pharmacokinetic-modifying anchors |
| CN112280800B (zh) * | 2020-10-19 | 2022-06-07 | 上海市东方医院（同济大学附属东方医院） | 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用 |
| EP4267741A2 (en) * | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| WO2022144883A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| KR102732910B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732911B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732909B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| WO2023210713A1 (ja) * | 2022-04-27 | 2023-11-02 | 国立大学法人京都大学 | 心外膜細胞再生促進剤および心外膜細胞の再生促進方法 |
| TW202529777A (zh) * | 2023-09-28 | 2025-08-01 | 日商日東電工股份有限公司 | 組合療法 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970005898B1 (ko) | 1987-09-21 | 1997-04-21 | 젠- 프로우브 인코퍼레이티드 | 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약 |
| US5204241A (en) | 1990-10-22 | 1993-04-20 | Oxi-Gene Inc. | Glutathione-S-transferase mu as a measure of drug resistance |
| US5786336A (en) | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| EP0748382B1 (en) | 1993-09-02 | 2002-11-06 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| JPH09504297A (ja) | 1993-10-27 | 1997-04-28 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ２′−アミドおよび２′−ペプチド修飾オリゴヌクレオチド |
| DE69633722T2 (de) | 1995-06-07 | 2005-11-03 | TELIK, INC., Palo Alto | Stoffwechseleffekt von bestimmten glutation analogen |
| US5968737A (en) * | 1996-11-12 | 1999-10-19 | The University Of Mississippi | Method of identifying inhibitors of glutathione S-transferase (GST) gene expression |
| JPH10330249A (ja) * | 1997-05-30 | 1998-12-15 | Kureha Chem Ind Co Ltd | レチノール化合物含有ｈｓｐ４７合成抑制剤 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999054346A1 (en) | 1998-04-16 | 1999-10-28 | Teijin Limited | Glutathione derivatives and dosage forms thereof |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20070083945A1 (en) * | 2000-03-10 | 2007-04-12 | Byrum Joseph R | Nucleic acid molecules and other molecules associated with plants |
| US20030144236A1 (en) | 2000-03-29 | 2003-07-31 | Weiss Robert H | Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1) |
| IL154129A0 (en) | 2000-07-28 | 2003-07-31 | Compugen Inc | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
| BRPI0115814B8 (pt) | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas |
| EP1627061B1 (en) | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| WO2004055165A2 (en) | 2002-12-13 | 2004-07-01 | St. Jude Children's Research Hospital | Glutathione-s-transferase test for susceptibility to parkinson's |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US20050142596A1 (en) | 2003-11-14 | 2005-06-30 | Krolewski Andrzej S. | Methods of diagnosing renal and cardiovascular disease |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005243410B2 (en) | 2004-05-14 | 2010-04-22 | Rosetta Genomics Ltd. | Micronas and uses thereof |
| MX2007002294A (es) * | 2004-08-26 | 2007-10-19 | Engeneic Molecular Delivery Pty Ltd | Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente. |
| EP2727583B1 (en) | 2004-12-22 | 2021-11-17 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
| US9393315B2 (en) * | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| JP2008536874A (ja) | 2005-04-15 | 2008-09-11 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | 中性脂質組成物によるｓｉＲＮＡの送達 |
| WO2007072220A2 (en) * | 2005-09-12 | 2007-06-28 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing cancer |
| ES2324128A1 (es) * | 2005-09-29 | 2009-07-30 | Proyecto De Biomedicina Cima, S.L. | Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares. |
| US20090220956A1 (en) | 2005-10-25 | 2009-09-03 | Dimitry Serge Antoine Nuyten | Prediction of Local Recurrence of Breast Cancer |
| RU2448974C2 (ru) * | 2005-11-01 | 2012-04-27 | Элнилэм Фармасьютикалз, Инк. | РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА |
| KR20080086440A (ko) | 2005-11-01 | 2008-09-25 | 알닐람 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 ＲＮＡｉ 억제 |
| WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
| ATE422162T1 (de) * | 2005-11-17 | 2009-02-15 | Childrens Medical Center | Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen |
| US7729737B2 (en) | 2005-11-22 | 2010-06-01 | Isense Corporation | Method and apparatus for background current arrangements for a biosensor |
| ES2419106T3 (es) | 2005-12-01 | 2013-08-19 | Pronai Therapeutics, Inc. | Formulación de liposomas anfóteros |
| US9572886B2 (en) * | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| WO2007130604A2 (en) * | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
| CN101484588B (zh) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| US8067390B2 (en) | 2007-03-02 | 2011-11-29 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of interleukins using siRNA in neutral liposomes |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| EA201000085A1 (ru) * | 2007-07-05 | 2010-10-29 | Новартис Аг | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ |
| ES2873350T3 (es) * | 2007-08-27 | 2021-11-03 | 1Globe Health Inst Llc | Composiciones de ARN interferente asimétrico y usos de las mismas |
| WO2009033284A1 (en) * | 2007-09-14 | 2009-03-19 | Mcmaster University | Inhibitors of collagen biosynthesis as anti-tumor agents |
| PT2268628E (pt) * | 2008-03-06 | 2012-06-28 | Rottapharm Spa | Derivados de 2-aril e de 2-heteroaril 4h-1-benzopiran-4-ona- 6-amidino para o tratamento de artrite, cancro e dores relacionadas |
| EP2321414B1 (en) * | 2008-07-25 | 2018-01-10 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
| EP2323693B1 (en) * | 2008-07-30 | 2017-11-08 | Nitto Denko Corporation | Drug carriers |
| CN107028886A (zh) * | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| KR101718534B1 (ko) | 2009-12-09 | 2017-03-22 | 닛토덴코 가부시키가이샤 | Ｈｓｐ４７ 발현의 조절 |
| EP2539469A4 (en) | 2010-02-24 | 2013-07-31 | Bodysync Inc | METHOD FOR DETERMINING GENE NUTRITIONAL INTERACTIONS |
| US20130004494A1 (en) | 2010-03-12 | 2013-01-03 | Ellen Heber-Katz | Inhibition of P21 and Use Thereof for Inducing Tissue Regeneration |
| US8372819B2 (en) | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| EP2566955A4 (en) | 2010-05-06 | 2014-10-29 | Stem Cell Medicine Ltd | STEM CELL BANK FOR PERSONALIZED MEDICINE |
| JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| WO2012044620A2 (en) * | 2010-09-30 | 2012-04-05 | Nitto Denko Corporation | Modulation of timp1 and timp2 expression |
| CN110123830A (zh) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法 |
| US9011903B2 (en) * | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| CN107043334B (zh) | 2011-06-08 | 2020-06-16 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| JP6023709B2 (ja) * | 2011-06-21 | 2016-11-09 | 日東電工株式会社 | アポトーシス誘導剤 |
| CN102896619B (zh) * | 2011-07-26 | 2015-04-22 | 苏州宝时得电动工具有限公司 | 动力工具及其操作方法 |
| CA2846074A1 (en) * | 2011-08-31 | 2013-05-10 | Alexzander A. Asea | Compositions and methods for treatment of metastatic cancer |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| CA2856117A1 (en) * | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np) |
| EP3424511A1 (en) * | 2012-05-16 | 2019-01-09 | Aadigen, LLC | Multi-target modulation for treating fibrosis and inflammatory conditions |
| US20140134158A1 (en) | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| EP2858974B9 (en) * | 2012-06-08 | 2022-07-20 | Nitto Denko Corporation | Lipids for therapeutic agent delivery formulations |
| WO2013192364A1 (en) | 2012-06-22 | 2013-12-27 | The University Of Vermont And State Agricultural College | Treatments of oxidative stress conditions |
| CN104684584A (zh) * | 2012-07-02 | 2015-06-03 | 费卜卢斯坦丁公司 | Gpbp-1的抑制及其治疗用途 |
| WO2014022739A2 (en) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| JP6340162B2 (ja) * | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| EP3608308B1 (en) * | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN103695421B (zh) | 2013-12-09 | 2016-06-15 | 浙江大学 | 一种特异抑制p21基因表达的siRNA及其应用 |
| CN113577290B (zh) * | 2014-12-26 | 2023-10-24 | 日东电工株式会社 | 细胞死亡诱导试剂、细胞增殖抑制试剂及用于治疗由细胞增殖异常导致的疾病的医药组合物 |
| US10792299B2 (en) * | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US20160187319A1 (en) | 2014-12-26 | 2016-06-30 | Nitto Denko Corporation | Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth |
| US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| KR102740699B1 (ko) * | 2015-12-13 | 2024-12-09 | 닛토덴코 가부시키가이샤 | 높은 활성 및 감소한 오프 타겟을 위한 sirna 구조 |
| JP6899201B2 (ja) | 2016-06-23 | 2021-07-07 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
-
2015
- 2015-11-06 US US14/934,665 patent/US10264976B2/en not_active Expired - Fee Related
- 2015-12-28 JP JP2017534286A patent/JP6793649B2/ja active Active
- 2015-12-28 CN CN201580071233.3A patent/CN107108686B/zh active Active
- 2015-12-28 KR KR1020177020901A patent/KR20170093988A/ko not_active Withdrawn
- 2015-12-28 JP JP2017534275A patent/JP2018512373A/ja active Pending
- 2015-12-28 RU RU2017126610A patent/RU2756253C2/ru active
- 2015-12-28 JP JP2017534279A patent/JP6865169B2/ja active Active
- 2015-12-28 WO PCT/US2015/067557 patent/WO2016106402A1/en not_active Ceased
- 2015-12-28 WO PCT/US2015/067556 patent/WO2016106401A2/en not_active Ceased
- 2015-12-28 CN CN201580071234.8A patent/CN108024961A/zh active Pending
- 2015-12-28 AU AU2015369598A patent/AU2015369598A1/en not_active Abandoned
- 2015-12-28 CN CN201580071081.7A patent/CN108064155B/zh active Active
- 2015-12-28 WO PCT/US2015/067553 patent/WO2016106400A2/en not_active Ceased
- 2015-12-28 RU RU2017126601A patent/RU2017126601A/ru unknown
- 2015-12-28 US US14/979,571 patent/US9695206B2/en active Active
- 2015-12-28 US US14/979,573 patent/US9580710B2/en not_active Ceased
- 2015-12-28 JP JP2017534274A patent/JP2018513104A/ja active Pending
- 2015-12-28 US US14/979,568 patent/US10405749B2/en active Active
- 2015-12-28 JP JP2017534297A patent/JP6457645B2/ja active Active
- 2015-12-28 EP EP15874365.8A patent/EP3236969A4/en not_active Withdrawn
- 2015-12-28 US US14/979,567 patent/US10047110B2/en active Active
- 2015-12-28 KR KR1020177020894A patent/KR20170098929A/ko not_active Withdrawn
- 2015-12-28 RU RU2017126613A patent/RU2719185C2/ru active
- 2015-12-28 WO PCT/US2015/067559 patent/WO2016106404A2/en not_active Ceased
- 2015-12-28 WO PCT/US2015/067561 patent/WO2016106406A2/en not_active Ceased
- 2015-12-28 BR BR112017013597-3A patent/BR112017013597B1/pt active IP Right Grant
- 2015-12-28 JP JP2017534294A patent/JP6730285B2/ja active Active
- 2015-12-28 US US14/979,577 patent/US20160215286A1/en not_active Abandoned
- 2015-12-28 EP EP15874362.5A patent/EP3236975A4/en not_active Ceased
- 2015-12-28 EP EP20156350.9A patent/EP3683309A1/en active Pending
- 2015-12-28 EP EP15874367.4A patent/EP3236973A4/en not_active Withdrawn
- 2015-12-28 CA CA2972265A patent/CA2972265A1/en not_active Abandoned
- 2015-12-28 KR KR1020177020900A patent/KR20170096199A/ko not_active Withdrawn
- 2015-12-28 US US14/979,574 patent/US10047111B2/en not_active Ceased
- 2015-12-28 AU AU2015369595A patent/AU2015369595A1/en not_active Abandoned
- 2015-12-28 EP EP15874364.1A patent/EP3236945B1/en active Active
- 2015-12-28 CA CA2971881A patent/CA2971881C/en active Active
- 2015-12-28 US US14/979,566 patent/US9771582B2/en not_active Ceased
- 2015-12-28 WO PCT/US2015/067558 patent/WO2016106403A2/en not_active Ceased
- 2015-12-28 CN CN201580071232.9A patent/CN107106564A/zh active Pending
- 2015-12-28 CA CA2972270A patent/CA2972270A1/en not_active Abandoned
- 2015-12-28 CA CA2972268A patent/CA2972268A1/en not_active Abandoned
- 2015-12-28 RU RU2017126598A patent/RU2017126598A/ru not_active Application Discontinuation
- 2015-12-28 CN CN201580071210.2A patent/CN108064153A/zh active Pending
- 2015-12-28 EP EP15874363.3A patent/EP3236976B1/en active Active
- 2015-12-28 EP EP20207751.7A patent/EP3798308A1/en active Pending
- 2015-12-28 KR KR1020177020898A patent/KR102527430B1/ko active Active
- 2015-12-28 CN CN201580071209.XA patent/CN107106592B/zh active Active
- 2015-12-28 EP EP15874366.6A patent/EP3240796B1/en active Active
- 2015-12-28 WO PCT/US2015/067560 patent/WO2016106405A1/en not_active Ceased
- 2015-12-28 JP JP2017534287A patent/JP2018513669A/ja active Pending
- 2015-12-28 CN CN201580071191.3A patent/CN107106591B/zh active Active
- 2015-12-28 BR BR112017013599-0A patent/BR112017013599A2/pt not_active Application Discontinuation
- 2015-12-28 EP EP15874361.7A patent/EP3236974B9/en active Active
- 2015-12-28 AU AU2015369596A patent/AU2015369596A1/en not_active Abandoned
- 2015-12-28 AU AU2015369592A patent/AU2015369592B2/en active Active
-
2017
- 2017-04-17 US US15/489,650 patent/US20170218365A1/en not_active Abandoned
- 2017-06-27 US US15/634,771 patent/US10023597B2/en active Active
-
2019
- 2019-09-19 US US16/576,102 patent/USRE48887E1/en active Active
-
2020
- 2020-02-28 US US16/804,696 patent/USRE49229E1/en active Active
- 2020-08-11 US US16/990,860 patent/USRE49431E1/en active Active
-
2021
- 2021-11-11 JP JP2021183788A patent/JP7307137B2/ja active Active
- 2021-11-12 US US17/454,757 patent/US20220087531A1/en not_active Abandoned
-
2023
- 2023-06-29 JP JP2023106970A patent/JP7655971B2/ja active Active
-
2025
- 2025-03-21 JP JP2025046972A patent/JP2025102833A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513104A5 (enExample) | ||
| Ashrafizadeh et al. | Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer | |
| Khan et al. | MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer | |
| Li et al. | Targeting long non-coding RNAs in cancers: progress and prospects | |
| Gandhi et al. | Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances | |
| Sadakierska-Chudy | MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics | |
| Hosseinahli et al. | Treating cancer with microRNA replacement therapy: A literature review | |
| Misso et al. | Mir-34: a new weapon against cancer? | |
| Swaminathan et al. | RNA interference and nanotechnology: A promising alliance for next generation cancer therapeutics | |
| Krützfeldt | Strategies to use microRNAs as therapeutic targets | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| Biersack | Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention | |
| Fahmy et al. | Molecular engines, therapeutic targets, and challenges in pediatric brain tumors: a special emphasis on hydrogen sulfide and RNA-based nano-delivery | |
| EA201890864A1 (ru) | Композиции и способы для ингибирования генной экспрессии лпа | |
| JP2014526450A5 (enExample) | ||
| HK1252852A1 (zh) | 阻止HIF2α基因表达的组合物及方法 | |
| Solé et al. | MicroRNAs and metastasis | |
| Yang et al. | Potential of miRNA-based nanotherapeutics for uveal melanoma | |
| Mollah et al. | Overcoming therapy resistance and relapse in TNBC: Emerging technologies to target breast cancer-associated fibroblasts | |
| Ballarín-González et al. | Polycation-based nanoparticles for RNAi-mediated cancer treatment | |
| Teo et al. | Tiny miRNAs play a big role in the treatment of breast cancer metastasis | |
| JP2016526021A5 (enExample) | ||
| Ciccone et al. | The small RNA landscape in NSCLC: current therapeutic applications and progresses | |
| Mirzaei et al. | MicroRNAs in cancer | |
| Maduri | Applicability of RNA interference in cancer therapy: current status |